CM-272

• Description:

  CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; DNA Methyltransferase; Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cm-272.html

• Concentration:

  10mM

• Purity:

  98.70

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  CN(CC1)CCC1NC2=CC(C3=CC=C(C)O3)=NC4=CC(OCCCN5CCCC5)=C(OC)C=C42

• Molecular Formula:

  C28H38N4O3

• Molecular Weight:

  478.63

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]San José-Enériz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  DNMT1; DNMT3; EHMT1/GLP/KMT1D; EHMT2/G9a/KMT1C

• CAS Number:

  [1846570-31-7]